Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,001 shares of NTLA stock, worth $111,947. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,001
Previous 3,464
15.5%
Holding current value
$111,947
Previous $24,000
54.17%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding NTLA
# of Institutions
333Shares Held
97MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$364 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$304 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$269 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$115 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$113 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $2.13B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...